WASHINGTON (Reuters) – The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company’s former executives for misleading claims about the results of Alzheimer’s clinical trials.
The SEC said the company’s founder and former CEO, Remi Barbier, and its former senior vice president of neuroscience, Dr. Lindsay Burns, will pay more than $40 million to settle charges.
(Reporting by Jasper Ward; Editing by Chris Reese)
Comments